Edwards Lifesciences Corp Form 4 Filings

Edwards Lifesciences Corp (EW) reported an insider sale by Annette Bruls, CVP, EMEACLA. On 2026-08-28, she sold 2,644 shares of Common Stock at $89.98 per share in an open market or private transaction. Following this sale, she directly holds 17,984 shares of Edwards Lifesciences common stock.

Edwards Lifesciences Corp (EW) executive Daveen Chopra, CVP, TMTT, Surgical & IHFM, exercised 31,800 Employee Stock Options for Common Stock at an exercise price of $72.68 per share and simultaneously sold 31,800 shares of Common Stock on 2026-08-26 in open-market transactions. The sales comprised 1,154 shares at a weighted average price of $91.7614 (individual trades ranged from $91.660 to $91.975) and 30,646 shares at a weighted average price of $90.9922 (trades ranged from $90.645 to $91.640). The option, originally exercisable since 2021-05-07 and expiring on 2027-05-06, now shows 0 options remaining in this grant.

Edwards Lifesciences Corp (EW) reported an insider sale by Wayne Markowitz, CVP, JAPAC. On 2026-08-26, he sold 1,240 shares of Common Stock in a sale classified as an open market or private transaction at a reported price of $91.465 per share. After this transaction, he directly holds 20,293.5581 shares of Edwards Lifesciences common stock. The filing notes that it reflects only changes in beneficial ownership and does not list all securities beneficially owned.

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported an option exercise and related stock sale. He exercised 619 Employee Stock Options at an exercise price of $72.68 per share, receiving 619 shares of Common Stock, and then sold 619 shares of Common Stock at $92.03 per share. Following the option exercise, he reported holding 4,333 options for Common Stock. The equity trades referencing the plan were effected pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026.

Edwards Lifesciences Corp executive Wayne Markowitz, CVP, JAPAC, reported selling 146.3127 shares of Common Stock on July 30, 2026, in a sale described as an open-market or private transaction at $86.0338 per share. After this sale, he directly holds 21533.5581 shares. The transaction was not designated as pursuant to a Rule 10b5-1 trading plan.

Wayne Markowitz, CVP, JAPAC at Edwards Lifesciences, exercised employee stock options covering 9,628 shares of common stock at $74.02 per share on July 28, 2026, then sold 9,628 shares at $85.06 per share the same day. Following the exercise, 9,628 derivative option securities are reported as held.

Edwards Lifesciences Corp CEO Bernard J. Zovighian reported several Common Stock transactions dated July 27, 2026. He made bona fide gifts totaling 639.2998 shares, moving 319.6499 shares out of direct ownership and 319.6499 shares into a trust, while an affiliated trust sold 2,920.5511 shares at $83.9342 per share. Following these changes, he directly held 98,845 shares, with an additional 3,733.5603 shares held indirectly through a 401(k).

Edwards Lifesciences Corp corporate vice president Annette Bruls reported a routine tax-related share disposition. On 2026-07-11, 109 shares of common stock were withheld at $92.21 per share to satisfy tax withholding obligations tied to vesting under Rule 16b-3(e). Following this withholding, she holds 20,628 shares of Edwards Lifesciences common stock directly.

Mistras Theodora reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp reported that its CVP, Chief Financial Officer Theodora Mistras received multiple equity awards on July 9, 2026 under the company’s Long-Term Stock Incentive Compensation Program. The awards include restricted stock units, performance-based restricted stock units, and employee stock options with multi‑year vesting schedules tied to continued service and, for the performance units, achievement of specified performance goals.

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, exercised employee stock options for 619 shares of common stock at $72.68 per share and, in a related open-market transaction, sold 619 shares at $91.70 per share on July 10, 2026. Following these transactions, he holds 40,033.9103 common shares directly and 4,952 employee stock options. The activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2026.

Edwards Lifesciences Corp executive Daniel J. Lippis reported a small, routine share disposition tied to tax withholding. On the vesting of equity awards, the issuer withheld 377 shares of common stock at $95.18 per share to cover tax obligations under Rule 16b-3(e).

After this tax-withholding event, Lippis directly holds about 40,033.9103 shares of Edwards Lifesciences common stock. The transaction reflects compensation-related tax settlement rather than an open-market sale or a change in his investment stance.

Edwards Lifesciences Corp corporate vice president Daniel J. Lippis exercised and sold a small block of shares under a pre-planned program. He exercised employee stock options to acquire 619 shares of common stock at $72.68 per share, then sold 619 shares in an open-market sale at a weighted average price of $91.4002 per share.

The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026, indicating they were pre-scheduled. After these trades, Lippis directly holds about 40,410.9103 shares of common stock and 5,571 employee stock options.

Edwards Lifesciences Corp CEO Bernard J. Zovighian reported an open-market sale of 523 shares of Common Stock at $87.92 per share. The shares were held indirectly through a trust, which held 11,516.5511 shares after the transaction.

The filing also shows 3,733.5603 shares held indirectly through a 401(k) plan and 99,164.6499 shares held directly as of the same date. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating it was scheduled in advance.

Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported an open-market sale of Common Stock. He sold 567.5266 shares at a price of $86.08 per share and now directly holds 15,334.0948 shares, indicating a relatively small reduction in his position.

Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP of Strategy and Corporate Development, reported an open-market sale of common stock indirectly held through a trust. The filing shows the trust sold 23,145 shares at a weighted average price of $86.4201 per share, with individual trades executed between $86.27 and $86.57. After this transaction, the trust still holds 98,611 shares. Separate holding entries show 30,969.5756 shares held indirectly through a 401(k) plan and 22,798.2532 shares held directly, providing additional context on his overall ownership.

Edwards Lifesciences Corp executive Daveen Chopra, CVP, TMTT & Surgical, reported an open-market sale of 1,500 shares of common stock. The shares were sold at a weighted average price of $84.6035 per share in multiple trades between $84.6002 and $84.6050. Following this transaction, Chopra directly holds 44,324 shares of Edwards Lifesciences common stock.

Edwards Lifesciences Corp executive Daniel J. Lippis reported an option exercise and related share sale under a pre-planned Rule 10b5-1 trading plan. On 2026-05-18, he exercised employee stock options for 620 shares of common stock at an exercise price of $72.68 per share and sold 620 shares in an open-market transaction at $81.14 per share.

Following these transactions, Lippis directly held about 40,410.9103 shares of common stock and 6,190 employee stock options exercisable into common shares. Because the activity was executed pursuant to a Rule 10b5-1 plan adopted on February 13, 2026, the timing appears routine rather than discretionary.

Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP of Strategy and Corporate Development, reported open-market sales of company common stock. On May 15, 2026, he sold 8,000 shares indirectly through a 401(k) account at $81.8216 per share and 9,968 shares directly at $82.0732 per share. A footnote notes the directly held sale was executed in multiple trades with prices ranging from $81.975 to $82.260, and the reported price is a weighted average. After these transactions, he held 22,798.2532 shares directly, 30,969.5756 shares indirectly via the 401(k), and 121,756 shares indirectly in a trust.

Edwards Lifesciences CEO Bernard J. Zovighian reported several stock transactions. On May 11, 2026, he exercised 47,207 Performance Rights into common stock, with 26,198 shares withheld at $79.96 per share to cover tax obligations, leaving him with additional net shares rather than an open-market sale. The filing notes these vested from performance-based restricted stock units granted in May 2023, after the board’s committee certified 167.70% of the target as earned.

On May 12, 2026, a trust associated with him sold a total of 36,351 common shares in open-market trades at weighted average prices around $78 per share, and there were two bona fide gifts totaling 53,280 shares between direct and trust holdings. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025. After the reported transactions, he holds about 99,165 shares directly, plus additional indirect holdings through a trust and a 401(k) plan.

Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP, Strategy/Corporate Development, reported the vesting and exercise of performance-based restricted stock units into 13,457 shares of common stock on May 11, 2026, after the board’s Compensation and Governance Committee certified 167.70% of the target award for vesting as of that date.

To satisfy related tax liability, 7,469 shares of common stock were withheld at $79.96 per share. Following these equity compensation transactions, he directly holds 32,766.2532 shares of Edwards Lifesciences common stock, alongside indirect holdings of 38,969.5756 shares in a 401(k) plan and 121,756 shares held by a trust.

Edwards Lifesciences Corp executive Daveen Chopra reported routine equity compensation activity involving performance-based restricted stock units. Chopra exercised performance rights covering 13,583 shares of common stock, linked to awards granted on May 11, 2023 with three-year performance vesting.

In connection with vesting, 7,538 shares of common stock were disposed of to cover tax obligations at a price of $79.96 per share, rather than through an open-market sale. Following these transactions, Chopra holds 45,824 shares of Edwards Lifesciences common stock directly.

The board’s Compensation and Governance Committee previously determined that 167.70% of the target number of performance-based units would vest as of May 11, 2026, and this Form 4 reflects the resulting share delivery and tax-withholding disposition.

Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem reported compensation-related equity transactions tied to performance-based restricted stock units. On May 11, 2026, he exercised 19,830 Performance Rights into the same number of common shares following the Compensation and Governance Committee’s decision that 167.70% of the target units would vest.

To cover tax obligations, 11,004 common shares were disposed of through a tax-withholding transaction at $79.96 per share, rather than via an open-market sale. After these transactions, he directly holds 46,740 common shares and indirectly holds 266,318 common shares through a trust. The Performance Rights exercised in this filing are now fully converted, with no remaining derivative position from this award.

Edwards Lifesciences Corp executive Wayne Markowitz, CVP, JAPAC, reported a mix of share sales and new equity awards. He completed an open-market sale of 593 shares of common stock at $79.73 per share on May 11, 2026, and held 21,679.8708 shares afterward.

On May 7, 2026, he received 5,200 restricted stock units and separate 5,200 performance-based restricted stock units under the Long-Term Stock Incentive Compensation Program, plus 26,400 employee stock options with a $82.76 exercise price, all vesting in installments starting one year after grant.

On May 7 and May 8, a total of 490 shares of common stock were disposed of as tax-withholding transactions related to equity compensation, rather than open-market sales.

Edwards Lifesciences CEO Bernard J. Zovighian reported multiple equity compensation and routine share transfers. On May 7, 2026, he received 43,800 restricted stock units and 43,800 performance-based stock units under the company’s Long-Term Stock Incentive Compensation Program, plus options for 245,300 shares of common stock at an exercise price of $82.76 per share.

The time-based restricted stock units are scheduled to vest in four equal annual installments starting one year after grant, while the performance units are scheduled to vest on May 7, 2029 based on three-year performance goals. On the same date, options are scheduled to vest in 36 approximately equal monthly installments beginning one month after grant.

He also reported bona fide gifts totaling 19,422 shares and tax-withholding dispositions totaling 9,551 shares between May 7–11, 2026. After these transactions, he holds 104,795.6499 shares directly, 21,750.5511 shares indirectly through a trust, and 3,733.5603 shares indirectly via a 401(k) plan.

Edwards Lifesciences Corp executive Daniel J. Lippis reported a small tax-related share disposition. On May 11, 2026, 362 shares of common stock were disposed of at $79.96 per share to cover tax obligations. After this non-market transaction, he directly holds about 40,410.91 shares.

VALERIANI NICHOLAS J reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp director Nicholas J. Valeriani received 5,127 restricted stock units as equity compensation. The award was granted on May 8, 2026 under the company’s 2020 Nonemployee Directors Stock Incentive Program and will become fully vested after one year from the grant date or at the next annual stockholders’ meeting, whichever comes first. Following this grant, he directly holds 84,423 shares of common stock. This is a non-cash, routine director compensation grant rather than an open-market share purchase.

Edwards Lifesciences Corp director Ramona Sequeira reported an equity award and updated holdings. She received a grant of 3,251 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share, classified as a grant/award acquisition. After this grant, her directly held common stock position is 6,779 shares.

The filing also shows an indirect holding of 14,076 shares of Common Stock held by trust. According to the grant terms, these restricted stock units were awarded on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and are scheduled to become 100% vested after the earlier of one year from the grant date or the company’s next annual meeting of stockholders.

LORANGER STEVEN R reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences director Steven R. Loranger reported equity awards and updated holdings. On May 8, 2026, he received 1,064 restricted stock units and a 3,251-share restricted stock award at $0.00 per share under the 2020 Nonemployee Directors Stock Incentive Program. Both awards are scheduled to vest 100% after the earlier of one year from the grant date or the company’s next annual stockholders’ meeting. Following these grants, he directly holds 8,997 shares and indirectly holds 75,372 shares through a trust.

LAVIOLETTE PAUL A reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp director Paul A. LaViolette received an equity grant of 3,251 restricted stock units on May 8, 2026. The award was granted at no cash price under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. These restricted stock units are scheduled to become 100% vested after the earlier of one year from the grant date or the company’s next annual meeting of stockholders. Following this grant, LaViolette directly holds 17,552 shares of common stock.

STONE HEISZ LESLIE reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp director Leslie Stone Heisz received a grant of 3,251 restricted stock units on May 8, 2026 under the company’s 2020 Nonemployee Directors Stock Incentive Program. These units are scheduled to become 100% vested after the earlier of one year from the grant date or the next annual meeting of stockholders. Following this award, the director holds 34,199 shares of common stock directly.

GALLAHUE KIERAN reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp director Kieran Gallahue reported equity awards on common stock. He received 1,064 restricted stock units and a 3,251-share restricted stock award on May 8, 2026 under the 2020 Nonemployee Directors Stock Incentive Program, scheduled to vest 100% after the earlier of one year from grant or the next annual stockholders meeting. Following these grants, he holds 4,315 shares directly and 79,656 shares indirectly by trust.

Feinberg David T reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp director David T. Feinberg received an equity grant of 3,251 shares of common stock in the form of restricted stock units. The award was granted at a price of $0.00 per share under the company’s 2020 Nonemployee Directors Stock Incentive Program.

The units are scheduled to become 100% vested after the earlier of one year from the May 8, 2026 grant date or the company’s next annual meeting of stockholders. Following this grant, Feinberg holds a total of 9,087 shares of common stock directly.

Edwards Lifesciences Corp executive Donald E. Bobo Jr., CVP of Strategy and Corporate Development, reported new equity awards and related tax-withholding transactions in company stock. He received 7,850 restricted stock units and 7,850 performance rights on May 7, 2026 under the company’s Long-Term Stock Incentive Compensation Program. He was also granted 44,000 employee stock options with a conversion price of $82.76 per share, vesting in approximately equal monthly installments over 36 months starting one month after grant. The restricted stock units are scheduled to vest in four equal annual installments beginning one year after grant, while the performance-based units are scheduled to vest on May 7, 2029 based on three-year performance goals.

To cover tax obligations, Bobo had 831 shares disposed at $83.20 per share on May 7, 2026 and 1,038 shares disposed at $82.76 per share on May 8, 2026, both classified as tax-withholding dispositions rather than open-market sales. Following these transactions, he directly holds 26,778.2532 shares of common stock, with additional indirect holdings of 121,756 shares via a trust and 38,969.5756 shares through a 401(k) plan.

Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem reported routine share dispositions to cover tax obligations tied to equity compensation. On May 7 and 8, a total of 3,034 common shares were withheld at prices of $83.20 and $82.76 per share. These were issuer tax-withholding transactions, not open-market sales. Ullem now holds 37,914 shares directly and 266,318 shares indirectly through a trust.

Davis Leslie C. reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences Corp director Leslie C. Davis received a grant of 3,251 shares of common stock on May 8, 2026, reported as a stock award at no purchase price. The award was made under the 2020 Nonemployee Directors Stock Incentive Program and represents restricted stock units.

These units are scheduled to become 100% vested after the earlier of one year from the grant date or the company’s next annual meeting of stockholders. Following this grant, Davis directly holds a total of 9,834 shares of Edwards Lifesciences common stock.

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP TAVR, reported equity compensation awards and related tax withholding transactions in company stock. He received 7,850 shares of common stock as a grant and 7,850 performance rights tied to common stock, all under the company’s Long-Term Stock Incentive Compensation Program. He was also granted 39,900 employee stock options exercisable at $82.76 per share, scheduled to vest in four equal annual installments beginning one year after the grant date. To cover tax obligations on awards vesting, 450 shares and 309 shares of common stock were withheld at prices of $82.76 and $83.20 per share, respectively. After these transactions, Lippis directly holds 40,772.9103 shares of Edwards Lifesciences common stock.

Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported routine equity compensation changes. On May 7, 2026, he acquired 7,005 shares of Common Stock through grants at no cost and received employee stock options on 6,745 shares with an exercise price of $82.76 per share.

The restricted stock units and options were granted under the company’s Long-Term Stock Incentive Compensation Program and are scheduled to vest and become exercisable in four equal annual installments starting one year after the grant date. On May 8, 2026, 289 shares of Common Stock were withheld at $82.76 per share to cover tax obligations, leaving Dahl with 15,901.6214 shares of Common Stock held directly after these transactions.

Edwards Lifesciences executive Daveen Chopra, CVP TMTT & Surgical, reported routine equity compensation and related tax withholding transactions in company stock. On May 7, 2026, he received 9,675 restricted stock units and 9,675 performance-based rights, plus 49,100 stock options with an $82.76 exercise price, all granted under the Long-Term Stock Incentive Compensation Program.

The restricted stock units and options are scheduled to vest in four equal annual installments starting one year after the grant date, while the performance rights are scheduled to vest on May 7, 2029 based on three-year performance goals, with 0%–200% of the target potentially vesting. On May 7–8, 2026, a total of 1,815 shares of common stock were disposed of solely to cover tax obligations, not as open-market sales. After these transactions, Chopra directly holds 39,779 shares of common stock.

Edwards Lifesciences Corp executive Annette Bruls, CVP EMEACLA, received new equity awards and had a small tax-related share disposition. On May 7, 2026, she was granted 6,650 performance-based restricted stock units and 33,700 employee stock options tied to common stock.

The options have a conversion/exercise price of $82.76 per share and both the options and time-based restricted stock units vest in four equal annual installments starting one year after the grant date. The performance-based units, with a target of 6,650 shares, are scheduled to vest on May 7, 2029 based on performance over a three-year period, with payouts ranging from 0% to 200% of the target.

On May 8, 2026, 84 shares of common stock were disposed of at $82.76 per share to satisfy tax obligations, not as an open-market sale. Following these transactions, Bruls directly holds 20,737 shares of Edwards Lifesciences common stock.

Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem exercised employee stock options to acquire 13,000 shares of common stock at $59.2567 per share. These options related to an award exercisable since May 8, 2020 and expiring on May 7, 2026, and the filing shows this option position is now fully exercised.

To cover tax obligations, the company withheld 11,131 shares at $82.91 and 620 shares at $83.98, reported as tax-withholding dispositions rather than open-market sales. After these transactions, Ullem directly owns 40,948 shares and indirectly holds 266,318 shares of common stock through a trust.

Edwards Lifesciences CEO Bernard J. Zovighian reported routine share dispositions mainly related to gifts and tax withholding. On May 5, 2026, he made two bona fide gifts of common stock, transferring 523 shares from a trust and 523 shares from his direct holdings, both at a stated price of $0.00 per share, reflecting that no consideration was received. Earlier, on May 3, 2026, 515 shares were disposed of at $83.98 per share to satisfy tax obligations, a tax-withholding disposition rather than an open-market sale. Following these transactions, he continues to hold 80,257.6499 direct shares, 12,039.5511 shares indirectly through a trust, and 3,733.5603 shares indirectly in a 401(k) plan.

Edwards Lifesciences Corp CVP, TAVR Daniel J. Lippis reported option exercises, tax withholding, and open-market sales of company stock. On May 1, 2026, he exercised employee stock options for 1,019 shares at $59.2567 per share and sold 1,000 shares at $82.9889 plus 19 shares at $83.9880. On May 4, 2026, he exercised options for another 1,019 shares at $59.2567 and sold 1,019 shares at $83.98. A separate 252-share disposition on May 3, 2026 covered tax obligations. After these transactions, he directly held about 33,681.9103 shares of Edwards Lifesciences common stock. The filing notes all reported trades were effected under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Corp executive Daveen Chopra reported a routine tax-related share disposition. On the transaction date, 282 shares of common stock were withheld at $83.98 per share to cover tax obligations, leaving Chopra with 31,919 shares of Edwards Lifesciences common stock held directly after the transaction.

Edwards Lifesciences Corp executive Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development, reported routine share updates and a small tax-related disposition of company stock. The filing shows a tax-withholding disposition of 469 shares of common stock at $83.98 per share, leaving him with 20,797.2532 shares held directly.

The filing also reports indirect holdings of 121,756 common shares held by a trust and 38,969.5756 shares represented in a 401(k) plan account, based on the plan administrator’s most recent statement. Overall, this Form 4 reflects mainly administrative updates and tax withholding rather than open-market buying or selling.

Edwards Lifesciences CVP and Chief Financial Officer Scott B. Ullem exercised employee stock options for 13,000 shares of common stock at an exercise price of $59.2567 per share and sold 13,000 shares in open-market transactions. The sales occurred in two tranches at weighted average prices of $80.4963 and $79.7866 per share under a pre-arranged Rule 10b5-1 trading plan adopted on July 29, 2025. After these transactions, he holds 39,699 shares directly and 266,318 shares indirectly through a trust, resulting in a net reduction of 13,000 shares in his position.

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, exercised employee stock options for 1,019 shares of common stock at an exercise price of $59.2567 per share and immediately sold 1,019 shares at a weighted average price of $80.9840 per share.

These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 30, 2025, indicating they were scheduled in advance. Following the transactions, Lippis directly owns 33,933.9103 shares of Edwards Lifesciences common stock.

Edwards Lifesciences Corp corporate VP Donald E. Bobo Jr. exercised employee stock options for 22,680 shares of common stock at an exercise price of $59.2567 per share. On the same date, he sold a total of 22,680 shares in open-market transactions at weighted average prices of $80.5915 and $80.0494 per share.

After these transactions, he directly holds 21,266.2532 shares of common stock, with additional indirect holdings of shares represented in a 401(k) plan and a trust. The filing states that these trades were effected under a Rule 10b5-1 trading plan adopted on February 27, 2025.

Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem exercised options for 13,000 shares of common stock at $59.2567 per share on March 11, 2026, then sold all 13,000 shares in open-market transactions at weighted average prices of $84.4613 and $85.2079.

After these transactions, he holds 39,699 shares directly and 266,318 shares indirectly through a trust, so the 13,000-share sale represents a small portion of his total reported holdings. All transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 29, 2025, indicating they were scheduled in advance.

Edwards Lifesciences Corp corporate vice president Daniel J. Lippis exercised employee stock options for 1,019 shares of common stock at an exercise price of $59.2567 per share, then sold 1,019 shares of common stock at a weighted average price of $85.3822.

These transactions were executed on March 11, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on July 30, 2025. Following the sale, Lippis directly holds 33,933.9103 shares of Edwards Lifesciences common stock, indicating he retained the vast majority of his equity position.